

## Common Misconceptions

Despite meaningful advancements in cancer treatment, there are limited options approved by the FDA for patients who are newly diagnosed with glioblastoma (GBM), one of the most common and aggressive forms of primary brain cancer. Approved in 2015 for newly diagnosed GBM, Optune® was the first treatment in over 10 years to increase survival in this patient population.

Optune is a wearable and portable, FDA-approved device for the treatment of GBM. Optune creates low-intensity electric fields called Tumor Treating Fields, or TTFields. TTFields help slow or stop glioblastoma cells from dividing and may also cause some of them to die. Patients receive continuous treatment by wearing adhesive patches, or transducer arrays, that deliver TTFields to the location of a GBM tumor. These transducer arrays are connected to the device.

To assist with accurate and consistent reporting around Optune, we have clarified below three of the most common misconceptions.

**MISCONCEPTION:** Optune uses electricity or currents to ‘zap’ cancer

**TRUTH:** Optune creates low-intensity **electric fields**, called Tumor Treating Fields or TTFields. TTFields help slow or stop glioblastoma cells from dividing and may also cause some of them to die. Patients receive continuous treatment by wearing adhesive patches, or transducer arrays, that deliver TTFields to the location of a glioblastoma (GBM) tumor.

Tumor Treating Fields do not stimulate or heat tissue. TTFields work when cancer cells are dividing and do not disrupt healthy resting cells. Because TTFields do not enter the bloodstream, like a drug, they have not been shown to affect cells in other parts of the body. Mild to moderate skin irritation is the most common side effect reported.

**MISCONCEPTION:** Optune can be described as a hat, helmet, or cap

**TRUTH:** Patients receive continuous treatment with Optune by wearing **adhesive patches, or transducer arrays**, on the shaved scalp.

The arrays connect to a portable device that delivers therapy to the location of the GBM tumor. Novocure has ongoing clinical trials in multiple solid tumor indications, including indications where patients apply the arrays to the torso and abdomen.

**MISCONCEPTION:** Optune is an experimental treatment

**TRUTH:** Optune has been **FDA-approved** since 2011. Over 6,000 glioblastoma patients have been treated with Optune to date.



## Indications for Use

Optune® is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

## Important Safety Information

### Contraindications

Do not use Optune if you have an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune if you are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

### Warnings and Precautions

Use Optune only after receiving training from qualified personnel, such as your doctor, a nurse, or other medical personnel who have completed a training course given by Novocure™ (the device manufacturer).

Do not use Optune if you are pregnant, you think you might be pregnant or are trying to get pregnant. It is not known if Optune is safe or effective in these populations.

The most common ( $\geq 10\%$ ) adverse events involving Optune in combination with temozolomide were low blood platelet count, nausea, constipation, vomiting, fatigue, scalp irritation from device use, headache, convulsions, and depression.

The most common ( $\geq 10\%$ ) adverse events seen when using Optune alone were scalp irritation from device use and headache.

The following adverse reactions were considered related to Optune when using the device alone: scalp irritation from device use, headache, malaise, muscle twitching, fall and skin ulcer.

All servicing procedures must be performed by qualified and trained personnel.

Do not use any parts that do not come with the Optune Treatment Kit, or that were not sent to you by the device manufacturer or given to you by your doctor.

Do not wet the device or transducer arrays.

If you have an underlying serious skin condition on the scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune treatment.

Please visit [Optune.com/Safety](https://www.optune.com/safety) for Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.